Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Inclusion Criteria:

* Histologic documentation of primary lung carcinoma, non-squamous histology with EGFR mutation.
* Stage disease according to the 7th Edition of the American Joint Committee on Cancer staging system
* Not received radiotherapy, chemotherapy or other biological treatment
* Measureable disease
* Life expectancy of\>=12 months
* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0 or 1
* Absolute neutrophil count (ANC)\>=2,500/mm\^3
* Hemoglobin\>=9.0 g/dL
* Total bilirubin\<=1.5 x upper limit of normal(ULN)
* Serum glutamic oxaloacetic transaminase (SGOT) (aspartate transaminase \[AST\]) and serum glutamic pyruvic transaminase (SGPT) (alanine transferase \[ALT\])\<=2.5 x ULN in patients without liver or bone metastases; \<5 x ULN in patients with liver or bone metastases
* Cockcroft-Gault calculated creatinine clearance of\>=45 ml/min or creatinine\<=1.5 x ULN
* Prothrombin time (PT)\<=1.5 x ULN
* Partial thromboplastin time (PTT)\<=ULN
* Negative pregnancy test done\<=7 days prior to randomization, for women of childbearing potential only
* Provide informed written consent
* Willing to return to Sichuan cancer hospital for follow-up
* Willing to provide tissue and blood samples for correlative research purposes

Exclusion Criteria:

* Mixed, non-small cell and small cell tumors or mixed adenosquamous carcinomas with a predominant squamous component
* Known allergic to EGFR TKI any ingredients
* Prior chemotherapy or treatment for metastatic non-small cell lung cancer
* Immunocompromised patients (other than that related to the use of corticosteroids) including patients known to be human immunodeficiency virus (HIV) positive, per MD discretion
* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm
* Other active malignancy\<=3 years prior to randomization;
* Ongoing or active infection, symptomatic congestive heart failure , cardiac arrhythmia, psychiatric illness/social situations, or any other medical condition that would limit compliance with study requirements
* History of bleeding diathesis or coagulopathy
* Inadequately controlled hypertension (systolic blood pressure of\>150 mmHg or diastolic pressure\>100 mmHg on anti-hypertensive medications)
* Serious non-healing wound, ulcer, bone fracture, or have undergone a major surgical procedure, open biopsy, or significant traumatic injury \<=28 days or core biopsy \<=7 days prior to randomization
* Pregnancy or breast-feeding women
* Other situation which researchers think that doesn't fit into the group